Navigation Links
Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses
Date:1/7/2008

sed on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our divestiture of non-strategic assets, our restructuring initiatives, our operational strategy, our financial performance and our growth strategy. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward- looking statements to reflect any change in our expectations or in events, conditions
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program
2. Boston Scientific Announces Results for Third Quarter Ended September 30, 2007
3. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
4. The 58th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, Nov. 2-6
5. Boston Scientific Announces European Approval of Next-Generation Implantable Defibrillator
6. Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetixs Medical Advisory Board
7. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
8. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
9. Genzyme Begins Major Expansion of Boston Manufacturing Facility
10. Boston Scientific Releases Remote Monitoring Data from its Wireless LATITUDE(R) Patient Management System
11. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2015)... - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") today announced its results ... fiscal 2014 year-end financial statements and MD&A have been filed on SEDAR ... , 2014 , 2013 Revenue 3,968 , ... 1,326 , 1,703 , 2,231 , ... 3,377 , 4,562 Ebitda* 92 , 418 ...
(Date:4/29/2015)... EAST RUTHERFORD, N.J. , April 29, 2015 ... 2015 financial results will be released on Friday, May 1, ... The Company will host a conference ... Conference Call When: , Friday, ... Dial-in: , 1-888-468-2440 for U.S.1-719-325-2454 for International ...
(Date:4/29/2015)... 2015 The leading Regenerative Veterinary Medicine ... regenerative stem cell therapy has processed more than 11,000 ... discover a successful treatment for horses with potentially fatal ... signed a worldwide exclusive license for adipose-derived (fat derived) ... horse was treated in January 2004. Shortly after, the ...
(Date:4/29/2015)... - Northern Biologics Inc., a privately held biotechnology company ... strategic collaboration with Celgene Corporation.  As part of ... upfront cash payment. It will use the funds ... will have the right to receive additional future ... Under the agreement, Northern Biologics ...
Breaking Biology Technology:Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4VetStem Biopharma -Regenerative Cell Therapy has processed over 11,000 samples 2Northern Biologics and Celgene Enter Strategic Collaboration 2
... Robotics today announced,that the European Union (EU) ... results of the SafeChemo Project it sponsored ... objectives were to scientifically and,independently establish if ... system for the safe preparation of hazardous ...
... Jan. 5 Baxter,International Inc. and Halozyme Therapeutics, ... start of a Phase III clinical trial of ... as KIOVIG in the European,Union, with Halozyme,s recombinant ... of primary immunodeficiency (PID).,The purpose of this clinical ...
... BMP Sunstone,Corporation (Nasdaq: BJGP ) ("BMP ... Pharmaceutical Co., Ltd., has been granted high tech,status ... is awarded by the PRC to,recognize companies that ... revenues generated by their own proprietary patented or,innovative ...
Cached Biology Technology:Health Robotics Announces Results of the European Union-Sponsored SafeChemo Project 2Health Robotics Announces Results of the European Union-Sponsored SafeChemo Project 3Health Robotics Announces Results of the European Union-Sponsored SafeChemo Project 4Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients 2Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients 3Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients 4Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients 5BMP Sunstone Receives High Tech Status 2BMP Sunstone Receives High Tech Status 3
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ... - Global Strategic Business Report" report to their offering. ... Geometry in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Rest of World. Annual estimates and forecasts are ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report to ... for Iris Biometrics in US$ Thousands. The report provides separate ... Japan , Europe , ... , and Latin America . ...
(Date:3/18/2015)... , March 18, 2015 As mobile ... new revolutionary smart wallets and apps continue to be introduced ... entrenched in the mobile payment industry in focus today are:  ... Ltd. (NYSE: BABA ), Apple Inc. (NASDAQ: ... and Facebook Inc. (NASDAQ: FB ) ...
Breaking Biology News(10 mins):Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6
... Park, MD (July 27, 2010) -- Drug delivery inside ... a maze of aqueous solutions, lipid membranes, and barriers ... reported in the American Institute of Physics publication the ... model that accurately predicts the hydration free energy (HFE) ...
... Park, MD (July 27, 2010) -- Fluids experts writing ... is published by the American Institute of Physics, are ... accurately probe the properties of turbulence near walls. High-Reynolds-number ... in aeronautics, naval applications, energy conversion processes, manufacturing, mixing ...
... fish scientist has received the Robert H. Gibbs, Jr. ... knowledge of fish diversity. The honor to Dr. ... the Ichthyology Department, was announced earlier this month in ... Society of Ichthyologists and Herpetologists. The Gibbs award is ...
Cached Biology News:
...
...
... Zero Blunt TOPO PCR Cloning Kit ... for high-efficiency (>=95%) cloning of blunt-end ... polymerases. The kit includes the linearized ... for 5-minute bench-top ligations without ligase ...
Carp Vitellogenin ELISA System, 96 wells. ELISARange: 5.0-225 ng/ml.Sensitivity: 5.0 ng/ml.Sample volume: 100 ul.Suitable for use with Carp plasma samples.3-h protocol.Store at 2-8 C. Category: Drug ...
Biology Products: